在患有炎症性肠道疾病的患者中,Interleukin-6单基因多态性
Dorota Cibor1, Konrad Jablonski2, Danuta Owczarek3
1Department of Gastroenterology and Hepatology, Jagiellonian University Medical College, Kraków, Poland. dorota.cibor@gmail.com.
Folia medica Cracoviensia
|February 19, 2025
概括
介素-6 (IL-6) 基因多态 (174G/C) 似乎不会增加患炎症性肠病 (IBD) 的风险,包括性结肠炎 (UC) 和克罗恩病 (CD). 然而,IL-6变异可能会影响UC患者的疾病进展.
科学领域:
- 遗传学和分子生物学
- 胃肠病学 胃肠病学
- 免疫学 免疫学 免疫学
背景情况:
- 炎症性肠病 (IBD),包括性结肠炎 (UC) 和克罗恩病 (CD),代表着一个重要的全球健康挑战.
- 遗传因素,特别是单核酸多态性 (SNP),与IBD的发病和疾病过程有关.
- 介乐-6 (IL-6) 是一种关键的促炎细胞因子,在免疫反应和炎症中起着已知的作用.
研究的目的:
- 研究IL-6-174G/C基因多态化与IBD的临床过程之间的关联.
- 确定IL-6-174G/C多态性是否影响UC和CD患者的疾病活动,位置,并发症和炎症标志物.
主要方法:
- 一组105名IBD患者 (50名CD,55名UC) 和124名健康对照对IL-6-174G/C多态性进行了基因定型.
- 收集了包括疾病持续时间,位置,并发症和手术史在内的临床数据.
- 血清IL-6水平,纤维素,C反应蛋白 (CRP) 和其他生物化学参数被评估并与基因型和临床参数相关联.
主要成果:
- 在IBD患者和对照人群之间没有观察到IL-6-174G/C多态度频率的显著差异.
- 与GC和CC基因型相比,具有GG基因型的IBD患者的IL-6平均水平较高.
- 在GG和GC基因型的UC和CD患者中,IL-6和纤维素/CRP水平之间存在正相关性,但CC基因型中没有.
结论:
- IL-6-174G/C多态性与患IBD的风险增加无关.
- 在性结肠炎患者中,IL-6基因变异可能在调节疾病进程和炎症反应方面发挥作用.
相关概念视频
Inflammatory Bowel Disease I: Ulcerative Colitis
122
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
122
Inflammatory Bowel Disease II: Crohn's Disease
166
Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
166
Pleiotropy
39.5K
Pleiotropy is the phenomenon in which a single gene impacts multiple, seemingly unrelated phenotypic traits. For example, defects in the SOX10 gene cause Waardenburg Syndrome Type 4, or WS4, which can cause defects in pigmentation, hearing impairments, and an absence of intestinal contractions necessary for elimination. This diversity of phenotypes results from the expression pattern of SOX10 in early embryonic and fetal development. SOX10 is found in neural crest cells that form melanocytes,...
39.5K
Single Nucleotide Polymorphisms-SNPs
13.9K
A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
13.9K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
110
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
110
Inflammatory Bowel Disease IV: Pharmacological Management
95
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
95


